

## Form 144 Filer Information

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 144

## Form 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001714576

Filer CCC XXXXXXXX

Is this a LIVE or TEST Filing? ☒ LIVE ☐ TEST

## Submission Contact Information

Name

Phone

E-Mail Address

## 144: Issuer Information

Name of Issuer Lantern Pharma Inc.

SEC File Number 001-39318

Address of Issuer 1920 MCKINNEY AVENUE, 7TH FLOOR  
DALLAS  
TEXAS  
75201

Phone 972-277-1136

Name of Person for Whose Account the Securities are To Be Sold Bios Fund II, LP

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Affiliate (10% owner)

## 144: Securities Information

Title of the Class of Securities To Be Sold Common Stock

Name and Address of the Broker Sanders Morris Harris  
5950 Sherry Lane, Ste 470  
Dallas  
TX  
75225

Number of Shares or Other Units To Be Sold 30650

Aggregate Market Value 119841.50

Number of Shares or Other Units Outstanding 10664803

Approximate Date of Sale 02/27/2024

Name the Securities Exchange NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or

any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Common Stock
Date you Acquired	06/15/2020
Nature of Acquisition Transaction	Conversion of Shares in IPO
Name of Person from Whom Acquired	Issuer

Is this a Gift?

☐ Date Donor Acquired

Amount of Securities Acquired	221522
Date of Payment	06/15/2020
Nature of Payment	Conversion

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Bios Fund II, LP 1751 River Run Suite 400 Fort Worth TX 76107
Title of Securities Sold	Common Stock
Date of Sale	02/27/2024
Amount of Securities Sold	10620
Gross Proceeds	46697.20

## 144: Remarks and Signature

Remarks	
Date of Notice	02/28/2024

### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature	/s/ Daniel Schwarz
-----------	--------------------

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**